東陽光長江藥業：中期報告2023.pdf

1、CONTENTS2Financial Highlights財務摘要3Corporate Profile公司簡介6Management Discussion and Analysis管理層討論及分析53Corporate Governance and Other Information企業管治及其他資料62Review Report審閱報告64Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表65Consolidated Statement of Financial Positio

2、n綜合財務狀況表67Consolidated Statement of Changes in Equity綜合權益變動表69Condensed Consolidated Cash Flow Statement簡明綜合現金流量表71Notes to the Unaudited Interim Financial Report未經審核中期財務報告附註109Corporate Information公司資料目錄YICHANG HEC CHANGJIANG PHARMACEUTICAL CO.,LTD./INTERIM REPORT 20232Financial Highlights財務摘要 (RMB

3、000)（人民幣千元）Six months ended 30 June 2023截至二零二三年六月三十日止六個月Six months ended 30 June 2022截至二零二二年六月三十日止六個月Year ended 31 December截至十二月三十一日止年度 2022202120202019二零二二年二零二一年二零二零年二零一九年 Revenue營業額3,209,0021,293,3083,744,952913,7882,348,1136,224,024 Gross profit毛利2,563,937960,6572,846,074483,6991,996,5665,302,202

4、 Profit/(loss)from operations經營溢利（虧損）1,398,121100,611321,068(423,377)1,254,6402,473,556(Loss)/profit before taxation除稅前（虧損）溢利1,261,853(36,402)39,422(667,184)1,010,4342,269,053(Loss)/profit attributable to equity shareholders of the Company本公司權益股東 應佔（虧損）溢利1,029,495(32,798)76,603(587,649)839,4551,918,

5、709(Losses)/earnings per share每股（虧損）盈利 Basic(RMB cent)基本（人民幣：分）117(4)9(67)95216 Diluted(RMB cent)攤薄（人民幣：分）117(4)9(67)53207Total assets總資產13,444,19610,813,72111,889,80010,541,5819,561,2679,912,339Total liabilities總負債6,350,2714,825,4215,819,7994,520,8194,457,6085,289,184Net assets淨資產7,093,9255,988,300

6、6,070,0016,020,7625,103,6594,623,155Profitability盈利能力Gross profit margin毛利率79.9%74.3%76.00%52.9%85.0%85.2%Operating profit margin經營溢利率43.6%7.8%8.6%46.3%53.4%39.7%Net profit margin淨利潤率31.9%2.5%1.3%-64.3%35.7%30.6%3Corporate Profile公司簡介 中期報告2023 /宜昌東陽光長江藥業股份有限公司YiChang HEC ChangJiang Pharmaceutical Co